Interactions Between Plaquenil and Antidepressants

Critical Cardiac Risk: QT Prolongation

The American College of Cardiology recommends caution when combining Plaquenil with antidepressants due to additive QT interval prolongation, leading to potentially fatal cardiac arrhythmias, with certain antidepressants like citalopram, escitalopram, and tricyclic antidepressants being contraindicated or requiring extreme caution 1, 2
Hydroxychloroquine causes QT interval prolongation, and when combined with QT-prolonging antidepressants, creates an additive risk for torsades de pointes and sudden cardiac death, particularly in patients with pre-existing cardiac conditions 1, 2

Citalopram and escitalopram are contraindicated with hydroxychloroquine due to severe torsades de pointe risk, as recommended by the American Heart Association 1, 2
All serotonin reuptake inhibitors require caution due to QT prolongation risk, according to the National Institute of Mental Health 2, 3

The American College of Cardiology recommends monitoring electrolytes, particularly potassium levels, as hypokalemia dramatically increases arrhythmia risk, especially when combining hydroxychloroquine with antidepressants 1, 2
Concurrent electrolyte disturbances, such as hypokalemia from corticosteroids or diuretics, further amplify cardiac risk, and patients should be closely monitored, as advised by the European Society of Cardiology 1, 2

Hydroxychloroquine is a weak CYP2D6 inhibitor, and strong CYP2D6 inhibitors among antidepressants can theoretically increase hydroxychloroquine levels, requiring more careful monitoring for increased hydroxychloroquine levels and toxicity, as recommended by the FDA 1, 2

The American College of Cardiology advises against assuming all SSRIs are equivalent, as citalopram/escitalopram carry contraindication while sertraline is safer, and against overlooking over-the-counter medications that may further prolong QT, such as antihistamines or certain supplements 1, 2
The National Institute of Mental Health recommends checking for other QT-prolonging medications the patient may be taking, such as ondansetron, domperidone, or certain antibiotics, to minimize the risk of cardiac arrhythmias 1, 2

The American Heart Association identifies both hydroxychloroquine and tricyclic antidepressants (including amitriptyline) as medications that can cause sodium channel blockade, QRS prolongation, and life-threatening cardiotoxicity 4, 5, 6
Both hydroxychloroquine and amitriptyline are classified as sodium channel blockers that can cause QT interval prolongation, increasing the risk of torsades de pointes and sudden cardiac death 4, 5

The combination of hydroxychloroquine with tricyclic antidepressants like amitriptyline requires baseline ECG monitoring, regular follow-up ECGs, close monitoring for signs of cardiotoxicity, and electrolyte monitoring, particularly potassium levels 7, 8, 9

Electrolyte disturbances, particularly hypokalemia, further increase the risk of arrhythmias when using hydroxychloroquine with QT-prolonging medications like amitriptyline 9
The French Society for Oncology Pharmacy guidelines specifically warn against combining hydroxychloroquine with medications that have the same cardiac toxicity profile 7

If treatment with both medication classes is absolutely necessary, consider alternative antidepressants with lower QT prolongation risk, implement rigorous cardiac monitoring, maintain strict electrolyte monitoring, and be prepared to use sodium bicarbonate for treatment of life-threatening cardiotoxicity if it develops 4, 5, 8, 9